Luts & Greenleigh Group, Inc Bristol Myers Squibb CO Transaction History
Luts & Greenleigh Group, Inc
- $101 Billion
- Q4 2024
A detailed history of Luts & Greenleigh Group, Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Luts & Greenleigh Group, Inc holds 4,057 shares of BMY stock, worth $232,952. This represents 0.23% of its overall portfolio holdings.
Number of Shares
4,057
Previous 3,942
2.92%
Holding current value
$232,952
Previous $204 Million
12.49%
% of portfolio
0.23%
Previous 0.2%
Shares
3 transactions
Others Institutions Holding BMY
# of Institutions
2,632Shares Held
1.47BCall Options Held
31.5MPut Options Held
34.9M-
Vanguard Group Inc Valley Forge, PA189MShares$10.8 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY159MShares$9.11 Billion0.15% of portfolio
-
State Street Corp Boston, MA92.9MShares$5.33 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY77.9MShares$4.47 Billion0.33% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA60.3MShares$3.46 Billion0.65% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $122B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...